Search
Verteporfin
go.drugbank.com/drugs/DB00460ApprovedInvestigationalIt is used as a photosensitizer in photodynamic therapy to eliminate abnormal blood vessels in wet form macular degeneration. … Verteporfin accumulates in these abnormal blood vessels and, when stimulated by nonthermal red light with a wavelength of 693 nm in the presence of oxygen, produces highly reactive short-lived singlet
Paltusotine
go.drugbank.com/drugs/DB16277ApprovedInvestigationalPaltusotine is a selective somatostatin receptor agonist: It mimics the biological actions of endogenous somatostatin, which activates the somatostatin 2 receptor (SST2) to block the secretion of growth … [A274476] Paltusotine was approved by the FDA on September 25, 2025 for the treatment of acromegaly in adults.[L54061]
Categories: Somatostatin Receptor AgonistsApadamtase alfa
go.drugbank.com/drugs/DB15164ApprovedInvestigational[A262071] Apadamtase alfa, sold under the brand name Adzynma (ADAMTS13, recombinant-krhn), was approved by the FDA in November 2023 for use as an enzyme replacement therapy in patients with cTTP. … for cleaving large von Willebrand factor multimers and preventing the formation of microthrombi - this deficiency in ADAMTS13 is responsible for the microangiopathic complications associated with cTTP
Levopropoxyphene
go.drugbank.com/drugs/DB06793ApprovedWithdrawnLevopropoxyphene is a stereoisomer of propoxyphene in the form of 2S, 3R enantiomer. It was sold as an antitussive, but it was removed from the market in the 70s. … This drug presented different dosages and it was administered as a capsule or suspension.
Eliglustat
go.drugbank.com/drugs/DB09039ApprovedInvestigational[L41404,A7634] Eliglustat was approved by the FDA in August 2014 as an oral substrate reduction therapy for the first-line treatment of type 1 Gaucher disease. … [A3752,L41404] Gaucher disease is a rare genetic disorder characterized by the deficiency of acid β-glucosidase, an enzyme that converts glucosylceramide into glucose and ceramide.
Metandienone
go.drugbank.com/drugs/DB13586ApprovedWithdrawn[A254432] In the US, metandienone is a controlled substance under the Controlled Substances Act.[L44057] … Metandienone is an orally active anabolic androgenic steroid. It was introduced to the market in the 1960s but later discontinued and withdrawn from the market.
Emapalumab
go.drugbank.com/drugs/DB14724ApprovedInvestigationalEmapalumab, also known as NI-0501, is a fully human monoclonal antibody that targets interferon gamma.
Alogliptin
go.drugbank.com/drugs/DB06203ApprovedInvestigationalChemically, alogliptin is prepared as a benzoate salt and exists predominantly as the R-enantiomer (>99%). It undergoes little or no chiral conversion in vivo to the (S)-enantiomer. … Alogliptin is a selective, orally-bioavailable inhibitor of enzymatic activity of dipeptidyl peptidase-4 (DPP-4).
Categories: DPP-IV Inhibitors, Drugs Used in DiabetesPegsitacianine
go.drugbank.com/drugs/DB19098InvestigationalPegsitacianine is under investigation in clinical trial NCT05576974 (A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence … Imaging Agent for the Detection of Cancer, in Patients With Unknown Primary Head and Neck Cancer (ILLUMINATE STUDY)).
Zomepirac
go.drugbank.com/drugs/DB04828ApprovedWithdrawnThe manufacturer voluntarily removed Zomax tablets from the Canadian, US, and UK markets in March 1983.